PhInc. Modeling is a Contract Research Organization (CRO) specialized in quantitative pharmacology solutions to support biotechs in the development of drug candidates, new chemical entities, and biological entities. The company relies on the Model-Informed Drug Development (MIDD) approach to make informed decisions supported by analyses and modeling.

This strategy allows PhInc. Modeling to integrate quantitative modeling and simulations to optimize drug development, predict pharmacological responses, and identify the best dosing strategies.

By using mathematical models and simulations, PhInc. Modeling can anticipate the effects of a drug candidate in different populations and conditions, thereby reducing risks and costs associated with clinical development. Through MIDD, the company aims to improve the efficiency of clinical trials and accelerate the market entry of new treatments.